Seagen Inc. (SGEN) News
Filter SGEN News Items
SGEN News Results
|Loading, please wait...|
SGEN News Highlights
- SGEN's 30 day story count now stands at 2.
- Over the past 1 day, the trend for SGEN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about SGEN are DRUG, TSE and WASH.
Latest SGEN News From Around the Web
Below are the latest news stories about SEAGEN INC that investors may wish to consider to help them evaluate SGEN as an investment opportunity.
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Buying stocks simple for their high dividend yields is risky but these are three stocks the elite love regardless.
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
BOTHELL, Wash. & TOKYO, November 30, 2023--Seagen Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE:4503) today announced that on November 30, 2023 the U.S. Food and Drug Administration (FDA) accepted for priority review a supplemental Biologics License Application (sBLA) for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as a combination therapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC), a form of bladder cancer that has
Undervalued sleeper stocks always offer potential bargains to investors at cheap prices that can multiply investments quickly
Bill Gross, the Bond King, is wading into the world of equity arbitrage with these three stocks - but are they worth the risk for investors?
Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting
BOTHELL, Wash., November 03, 2023--Seagen Inc. (NASDAQ: SGEN) today announced the first presentation of data evaluating ADCETRIS® (brentuximab vedotin) in combination with an anti-PD-1 checkpoint inhibitor in non-small cell lung cancer (NSCLC) and melanoma, and shared preclinical data for an investigational CD30-directed antibody-drug conjugate (ADC) that uses a novel tripeptide linker. The studies were presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place
New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate
BOTHELL, Wash., November 02, 2023--Seagen Inc. (NASDAQ: SGEN) today announced that 12- and 24-month progression free survival data will be presented for an ADCETRIS® (brentuximab vedotin) and immunotherapy combination in early and advanced stage classical Hodgkin lymphoma (cHL), respectively. The data will be featured in two oral presentations at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 9-12, 2023 in San Diego. The ongoing Phase 2 clinical
The headline numbers for Seattle Genetics (SGEN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress
BOTHELL, Wash., November 01, 2023--Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the third quarter ended September 30, 2023.
Equities remain under pressure, but if you’re looking to be a contrarian investor, it’s a good time to look for undervalued long-term stocks